Literature DB >> 17163421

Androgen receptor coregulators and their involvement in the development and progression of prostate cancer.

Renée Chmelar1, Grant Buchanan, Eleanor F Need, Wayne Tilley, Norman M Greenberg.   

Abstract

The androgen receptor signaling axis plays an essential role in the development, function and homeostasis of male urogenital structures including the prostate gland although the mechanism by which the AR axis contributes to the initiation, progression and metastatic spread of prostate cancer remains somewhat enigmatic. A number of molecular events have been proposed to act at the level of the AR and associated coregulators to influence the natural history of prostate cancer including deregulated expression, somatic mutation, and post-translational modification. The purpose of this article is to review the evidence for deregulated expression and function of the AR and associated coactivators and corepressors and how such events might contribute to the progression of prostate cancer by controlling the selection and expression of AR targets.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17163421     DOI: 10.1002/ijc.22365

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  96 in total

1.  Inhibitory effect of matrine on the expression of PSA and AR in prostate cancer cell line LNCaP.

Authors:  Ke Chen; Zhiquan Hu; Tao Wang; Hui Guo; Zhangqun Ye
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2008-12-24

2.  Deleted in breast cancer 1, a novel androgen receptor (AR) coactivator that promotes AR DNA-binding activity.

Authors:  Junjiang Fu; Jun Jiang; Jiwen Li; Shanshan Wang; Guang Shi; Qin Feng; Eileen White; Jun Qin; Jiemin Wong
Journal:  J Biol Chem       Date:  2009-01-05       Impact factor: 5.157

3.  Androgen modulation of coregulator expression in prostate cancer cells.

Authors:  Hannelore V Heemers; Kevin M Regan; Lucy J Schmidt; S Keith Anderson; Karla V Ballman; Donald J Tindall
Journal:  Mol Endocrinol       Date:  2009-01-22

4.  Testis-specific protein on Y chromosome (TSPY) represses the activity of the androgen receptor in androgen-dependent testicular germ-cell tumors.

Authors:  Chihiro Akimoto; Takashi Ueda; Kazuki Inoue; Ikuko Yamaoka; Matomo Sakari; Wataru Obara; Tomoaki Fujioka; Akira Nagahara; Norio Nonomura; Syuichi Tsutsumi; Hiroyuki Aburatani; Tsuneharu Miki; Takahiro Matsumoto; Hirochika Kitagawa; Shigeaki Kato
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-01       Impact factor: 11.205

Review 5.  New hormonal therapies for castration-resistant prostate cancer.

Authors:  Elahe A Mostaghel; Stephen Plymate
Journal:  Endocrinol Metab Clin North Am       Date:  2011-07-14       Impact factor: 4.741

Review 6.  Rationale for the development of alternative forms of androgen deprivation therapy.

Authors:  Sangeeta Kumari; Dhirodatta Senapati; Hannelore V Heemers
Journal:  Endocr Relat Cancer       Date:  2017-05-31       Impact factor: 5.678

7.  ERK and AKT signaling drive MED1 overexpression in prostate cancer in association with elevated proliferation and tumorigenicity.

Authors:  Feng Jin; Shazia Irshad; Wei Yu; Madesh Belakavadi; Marina Chekmareva; Michael M Ittmann; Cory Abate-Shen; Joseph D Fondell
Journal:  Mol Cancer Res       Date:  2013-03-28       Impact factor: 5.852

8.  Nemo-like kinase induces apoptosis and inhibits androgen receptor signaling in prostate cancer cells.

Authors:  Katayoon H Emami; Lisha G Brown; Tiffany E M Pitts; Xizhang Sun; Robert L Vessella; Eva Corey
Journal:  Prostate       Date:  2009-10-01       Impact factor: 4.104

9.  Alternative inhibition of androgen receptor signaling: peptidomimetic pyrimidines as direct androgen receptor/coactivator disruptors.

Authors:  Jillian R Gunther; Alexander A Parent; John A Katzenellenbogen
Journal:  ACS Chem Biol       Date:  2009-06-19       Impact factor: 5.100

10.  A novel androgen receptor-binding element modulates Cdc6 transcription in prostate cancer cells during cell-cycle progression.

Authors:  Feng Jin; Joseph D Fondell
Journal:  Nucleic Acids Res       Date:  2009-06-11       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.